Saturday, May 31, 2025

Latest

Mind Medicine Pays JR Rahn $6.7 Million In Shares To Leave Leadership Roles

It seems that after selling $24.7 million in company stock, JR Rahn is looking to step down from Mind Medicine (NEO: MMED) (NASDAQ: MNMD). The firm this morning announced that Rahn will be stepping down from his role as both CEO and director of the company in which in co-founded. The best part, is he will be paid to do so.

As part of the agreement for Rahn to step down from his role, the company has notably agreed to issue him 1.5 million subordinate voting shares. Effectively, Rahn will see a pay day equivalent to $6.68 million just for leaving his role as an executive of the company.

Taking Rahn’s place as CEO of the company will be that of Robert Barrow, the firms chief development officer, effective immediately. The company has also commence a “comprehensive search for a chief executive officer,” for which Barrow is to be a candidate, with Rahn advising the firm on its transition.

The transition reportedly will “enable the company to pursue aggressively its clinical development programs and development of its companion innovative digital technologies.” Commenting on his transition, Rahn stated, “Our work to date and ability to raise capital has taken us leaps and bounds closer to that vision. This chief executive officer transition is a natural progression for MindMed as the Company heads into later stage clinical trials.”

Mind Medicine last traded at $4.45 on the Neo.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

How To Profit From $3300 Gold? An Inside Look At A Massive 300,000 Oz Project | Martino De Ciccio

We’re At The Start of a Great Silver Boom | Ross McElroy & Andy Bowering – Apollo Silver Corp

Equinox Gold Q1 Earnings: When Everything Goes Wrong

Recommended

ESGold Begins Concentration Tests Ahead Of First Production

Sterling Metals Hits 0.21% Copper Over 482.8 Metres In First Drilling At Soo Copper project

Related News

Mind Medicine Sees Final Co-Founder Leave The Company

Mind Medicine (NEO: MMED) appears to now be fully under new management. On Friday evening,...

Sunday, January 9, 2022, 03:07:00 PM

Mindmed: Canaccord Calls Financing “Puzzling And Unusual”

This past week Mind Medicine Inc. (NEO: MMED) announced that they would be doing a...

Saturday, October 1, 2022, 01:04:00 PM

Mindmed To Conduct 15-To-1 Reverse Split To Meet Nasdaq Listing Requirements

In a classic Canadian small cap move, Mind Medicine (NEO: MMED) last night announced that...

Friday, August 5, 2022, 08:42:02 AM

Canaccord Reiterates $1.75 Price Target For Mind Medicine Following Roadshow Event

This morning, Canaccord released a flash update for Mind Medicine (NEO: MMED) with highlights from...

Monday, September 28, 2020, 11:02:24 AM

MindMed To Begin Trading On The Nasdaq April 27

MindMed (NEO: MMED) is moving up to the big leagues. The psychedelics company this morning...

Friday, April 23, 2021, 09:11:58 AM